Kestra Medical Technologies (NASDAQ:KMTS) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Kestra Medical Technologies (NASDAQ:KMTS) from a sell rating to a hold rating in a report issued on Saturday morning,Wall Street Zen reports.

Other equities research analysts have also recently issued reports about the stock. Weiss Ratings upgraded shares of Kestra Medical Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, September 16th. Piper Sandler reissued an “overweight” rating on shares of Kestra Medical Technologies in a research note on Tuesday, September 15th. Royal Bank Of Canada set a $30.00 price objective on shares of Kestra Medical Technologies in a report on Tuesday, September 15th. Oppenheimer assumed coverage on shares of Kestra Medical Technologies in a research report on Tuesday, July 21st. They set a “market perform” rating for the company. Finally, JPMorgan Chase & Co. initiated coverage on shares of Kestra Medical Technologies in a research report on Monday, August 10th. They set an “overweight” rating and a $30.00 price objective for the company. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $29.00.

Kestra Medical Technologies Stock Up 0.4%

NASDAQ KMTS opened at $29.81 on Friday. The stock has a fifty day simple moving average of $26.75 and a 200-day simple moving average of $23.86. The company has a current ratio of 4.69, a quick ratio of 4.69 and a debt-to-equity ratio of 0.33. Kestra Medical Technologies has a twelve month low of $17.34 and a twelve month high of $31.06.

Kestra Medical Technologies (NASDAQ:KMTS) last issued its quarterly earnings data on Monday, September 14th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by ($0.14). Kestra Medical Technologies had a negative net margin of 140.43% and a negative return on equity of 63.83%. The company had revenue of $30.97 million during the quarter. On average, sell-side analysts expect that Kestra Medical Technologies will post -2.45 earnings per share for the current year.

Insider Transactions at Kestra Medical Technologies

In related news, Director Raymond Cohen sold 3,330 shares of the stock in a transaction dated Wednesday, September 30th. The stock was sold at an average price of $29.28, for a total transaction of $97,502.40. Following the transaction, the director owned 54,790 shares of the company’s stock, valued at approximately $1,604,251.20. This represents a 5.73% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Traci Umberger sold 30,000 shares of the stock in a transaction dated Tuesday, October 27th. The stock was sold at an average price of $30.03, for a total value of $900,900.00. Following the transaction, the insider directly owned 195,825 shares in the company, valued at approximately $5,880,624.75. The trade was a 13.28% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 289,551 shares of company stock worth $8,171,898. 5.30% of the stock is owned by corporate insiders.

Institutional Trading of Kestra Medical Technologies

Institutional investors and hedge funds have recently bought and sold shares of the business. Sterling Capital Management LLC grew its holdings in shares of Kestra Medical Technologies by 834.0% in the third quarter. Sterling Capital Management LLC now owns 878 shares of the company’s stock valued at $25,000 after purchasing an additional 784 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Kestra Medical Technologies during the 3rd quarter worth approximately $353,000. Quantinno Capital Management LP purchased a new stake in Kestra Medical Technologies during the 1st quarter worth approximately $431,000. California State Teachers Retirement System increased its stake in Kestra Medical Technologies by 39.2% during the 1st quarter. California State Teachers Retirement System now owns 27,835 shares of the company’s stock worth $555,000 after buying an additional 7,844 shares during the period. Finally, Spartan Wealth Advisory Services LLC acquired a new stake in Kestra Medical Technologies during the 1st quarter worth approximately $603,000.

Kestra Medical Technologies Company Profile

Kestra Medical Technologies, Inc is a medical technology company focused on developing and commercializing wearable solutions for patients at risk of sudden cardiac arrest. Its primary product is the ASSURE wearable cardioverter defibrillator, a wearable device designed to continuously monitor a patient’s heart rhythm and deliver a therapeutic shock when clinically necessary.

The company’s platform combines cardiac monitoring, arrhythmia detection and defibrillation capabilities in a wearable system intended for use outside the hospital.